BCTXL

BriaCell announced its seventh consecutive positive DSMB recommendation for the pivotal Phase 3…

Monitor for next DSMB update or efficacy data readout from the Phase 3 Bria-ABC study. No near-term catalyst date provided; stock likely to remain range-bound until meaningful efficacy or safety…

BriaCell received FDA clearance of its Investigational New Drug (IND) application for Bria-PROS+…

The IND clearance is a near-term positive catalyst but expected for a clinical-stage biotech. Traders should watch for enrollment updates and any early safety/efficacy signals from the Phase 1/2a…

BriaCell announced that Sunnybrook's Odette Cancer Centre has joined its pivotal Phase 3 study of…

This is a routine clinical site activation with no new data, regulatory decision, or financing event. Monitor for future data readouts or regulatory milestones from the Phase 3 study for potential…

BriaCell (BCTXL) received a sixth consecutive positive recommendation from the independent DSMB to…

Positive DSMB safety readout reduces binary risk slightly but provides no efficacy signal. Phase 3 enrollment and interim analysis timelines are the next catalysts — monitor for enrollment…